First line chemotherapy in locally advanced and disseminated esophageal squamous cell carcinoma

Cover Page

Cite item

Full Text

Abstract

Retrospective analysis of the treatment results of 156 patients with locally advanced and disseminated esophageal squamous cell carcinoma was performed. The patient group included 124 (79.3 %) men (median age 64 years) and 32 (20.5 %) women (median age 63.4 years). Metastases were found primarily in the lymph nodes – 136 (87.2 %) cases, lungs – 44 (28.2 %) cases, liver – 38 (24.4 %) cases. The patients received treatment with a two-component drug combination: paclitaxel + carboplatin (ТР), or a four-component combination: docetaxel + cisplatin + leucovorin + 5-fluorouracil (mDCF). The mDCF combination showed higher rates of toxicity: hematogenic (neutropenia) and non-hematogenic (asthenia, weight loss, lower limb edema) complications. In 37 (23.7 %) patients, grade III and IV dysphagia were diagnosed. It was managed by endoscopic installation of self-expanding stents. Currently, despite toxic side symptoms, both schemes are safe and are the most commonly prescribed for locally advanced and disseminated esophageal squamous cell carcinoma.

About the authors

V. V. Sokolovskiy

Department of Oncology of the I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: Sokol.2012.vitya@mail.ru
ORCID iD: 0000-0003-0704-2265

Viktor Vladimirovich Sokolovskiy

Bld. 2, 8 Trubetskaya St., Moscow 119991

Russian Federation

References

  1. Petrillo A., Smyth E.C. Immunotherapy for squamous esophageal cancer: a review. J Pers Med 2022;12(6):862. doi: 10.3390/jpm12060862
  2. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49. doi: 10.3322/caac.21660
  3. Dvoretsky S.Y. Modern strategy for the treatment of esophageal cancer Vestnik khirurgii im. I.I. Grekova = Grekov’s Bulletin of Surgery 2016;175(4):102-7. (In Russ.).
  4. Abbas G., Krasna M. Overview of esophageal cancer. Ann Cardiothorac Surg 2017;6(2):131-6. doi: 10.21037/acs.2017.03.03
  5. Wong M.C.S., Hamilton W., Whiteman D.C. et al. Global incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. Sci Rep 2018;8(1):4522. doi: 10.1038/s41598-018-19819-8
  6. Jaffe D.H., Gricar J., DeCongelio M., Mackie D.S. A global perspective in second-line treatment patterns for patients with advanced esophageal squamous cell carcinoma. Thorac Cancer 2022;13(9):1240-57. doi: 10.1111/1759-7714.14334
  7. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013;19(34);5598-606. doi: 10.3748/wjg.v19.i34.5598
  8. Oncology: national guidelines. Ed. by V.I. Chissov, M.I. Davydov. Moscow: GEOTAR-Media, 2008. 1072 p. (In Russ.).
  9. Kauppila J.H., Mattsson F., Brusselaers N., Lagergren J. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. BMJ Open 2018;8(5):e021495. doi: 10.1136/bmjopen-2018-021495
  10. Yang Y., Jia J., Sun Z. et al. Association between multiple lines of active therapy and prognosis in esophageal squamous cell carcinoma cancer management and research. Cancer Manag Res 2020:12;2177-84. doi: 10.2147/CMAR.S242780
  11. Noone A.M., Cronin K.A., Altekruse S.F. et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomarkers Prev 2017;26(4):632-41. doi: 10.1158/1055-9965.EPI-16-0520
  12. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7-34. doi: 10.3322/caac.21551
  13. Dubecz A., Watson T.J., Raymond D.P. et al. Esophageal stenting for malignant and benign disease: 133 cases on a thoracic surgical service. Ann Thorac Surg 2011;92(6):2028-32; discussion 2032-3. doi: 10.1016/j.athoracsur.2011.08.033
  14. Thomson I.G., Smithers B.M., Gotley D.C. et al. Thoracoscopicassisted esophagectomy for esophageal cancer: analysis of patterns and prognostic factors for recurrence. Ann Surg 2010;252(2):281-91. doi: 10.1097/SLA.0b013e3181e909a2
  15. Lordick F., Mariette C., Haustermans K. et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl S5):v50-v7.
  16. NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf (Date of assess 29.12.2022).
  17. Kitagawa Y., Uno T., Oyama T. et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus 2019;16(1):25-43. doi: 10.1007/s10388-018-0642-8
  18. Tryakin А.А., Fedyanin М.Yu., Pokataev I.A. et al. Immunotherapy of gastrointestinal malignancies (gastroesophageal and colorectal carcinoma). Prakticheskaya onkologiya = Practical Oncology 2024;25(3):196-222. (In Russ.).
  19. Xu J., Bai Y., Li E. et al. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review. Exp Rev Anticancer Therapy 2022;22(9):981-98. doi: 10.1080/14737140.2022.2110470
  20. Napier K.J., Scheerer M., Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 2014;6(5):112-20. doi: 10.4251/wjgo.v6.i5.112
  21. Ghazanfar S., Qureshi S., Tariq F. et al. Palliative management of irresectablecarcinoma esophagus using selfexpandable metallic stent (SEMS). J Pak Med Assoc 2009;59(7):437-40
  22. Mohapatra S., Santharaman A., Gomez K. et al. Optimal management of dysphagia in patients with inoperable esophageal cancer: current perspectives. Cancer Manag Res 2022;14:3281-91. doi: 10.2147/CMAR.S362666
  23. Tryakin A.A., Besova N.S., Volkov N.M. et al. Practical guidelines for the drug treatment of cancer of the esophagus and esophagealgastric junction. Practical recommendations of RUSSCO, part 1.1. Zlokachestvennie opukholi = Malignant Tumors 2024;14(3s2):110-29. (In Russ.). doi: 10.18027/2224-5057-2024-14-3s2-1-1-12.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 ABV-Press

License URL: https://mdonco.abvpress.ru/jour/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-81466 от  03.08.2021.